Pemetrexed ditromethamine Hospira: Withdrawal of the marketing authorisation application



On 22 September 2016, Hospira UK Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Pemetrexed (as ditromethamine) Hospira, for the treatment of malignant pleural mesothelioma and non-small-cell lung cancer.

  • List item

    Questions and answers on the withdrawal of the marketing authorisation application for Pemetrexed ditromethamine Hospira (PDF/74.88 KB)

    First published: 14/10/2016
    Last updated: 14/10/2016

  • Key facts

    Pemetrexed ditromethamine Hospira
    Product number
    International non-proprietary name (INN) or common name
    • pemetrexed
    Active substance
    • pemetrexed ditromethamine
    Date of withdrawal
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating